Details for New Drug Application (NDA): 020903
✉ Email this page to a colleague
The generic ingredient in REBETOL is ribavirin. There are fifteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ribavirin profile page.
Summary for 020903
Tradename: | REBETOL |
Applicant: | Merck Sharp Dohme |
Ingredient: | ribavirin |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020903
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** | ||||
Approval Date: | Jun 3, 1998 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jul 25, 2001 | TE: | RLD: | Yes |
Expired US Patents for NDA 020903
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-002 | Jul 25, 2001 | 6,524,570*PED | ⤷ Subscribe |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | 6,337,090*PED | ⤷ Subscribe |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-002 | Jul 25, 2001 | 6,063,772*PED | ⤷ Subscribe |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-002 | Jul 25, 2001 | 6,461,605*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription